What's Happening?
Sangamo Therapeutics, a pioneering gene editing biotech company based in the Bay Area, has filed for Chapter 11 bankruptcy protection. The company has entered into asset sale agreements with Eli Lilly and Astellas Pharma. Eli Lilly will acquire Sangamo's
capsid delivery platform, zinc finger nuclease (ZFN) platform, modular integrase (MINT) platform, and prion disease program, ST-506. Astellas Pharma will take over Sangamo's Fabry disease program, isaralgagene civaparvovec (ST-920). These companies will act as 'stalking horse' bidders in a future bankruptcy court auction. Sangamo's CEO, Sandy Macrae, emphasized the strategic interest in their assets and the company's commitment to a disciplined sale process. Founded in 1995, Sangamo was an early developer of ZFNs, a gene editing platform, and has been involved in various clinical trials, including those for Fabry disease.
Why It's Important?
The bankruptcy filing and asset sales mark a significant shift for Sangamo, which has been a leader in gene editing technology. The involvement of major pharmaceutical companies like Eli Lilly and Astellas Pharma highlights the strategic value of Sangamo's assets. This development could impact the biotech industry, particularly in the field of gene therapy, as it may lead to further consolidation and collaboration among companies. Stakeholders, including employees and investors, face uncertainty as the company restructures. The outcome of the bankruptcy proceedings and asset sales will likely influence the future direction of gene editing technologies and their applications in medicine.
What's Next?
The next steps involve the bankruptcy court auction where Sangamo's assets will be sold. The outcome will determine the future ownership and development of Sangamo's technologies. Interested bidders may emerge for the remaining assets not included in the stalking horse bids. The company's restructuring efforts, including workforce reductions and pipeline narrowing, will continue as it focuses on developing epigenetic regulation therapies and novel delivery technologies. The biotech industry will be watching closely to see how these developments affect the competitive landscape and innovation in gene therapy.
